Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Carotid Intima-Media Thickness Versus Carotid Plaque Burden for Predicting Cardiovascular Risk

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Open Versus Endovascular Stent Graft Repair of Abdominal Aortic Aneurysms: Do We Need More Randomized Clinical Trials?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pre-operative autonomic nervous system function - a missing link for post-induction hypotension?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Genetic association study in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) identifies several potential risk loci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31 in Danish

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
The anemia in patients with chronic renal failure can be corrected through treatment with recombinant human erythropoietin treatment. This correction is associated with changes in the rheologic variables, which could explain the changes in hemodynamics found by many investigators. The authors have followed up 11 patients with chronic renal failure on hemodialysis before and during six months of therapy with erythropoietin. The measurements were made before treatment, after four months of therapy, and after six months of therapy. The measurements included hematocrit, osmotic resistance of the red blood cells, red blood cell volume, plasma volume, heart rate, arterial blood pressure, and cardiac output measured by the indicator dilution method. They found a significant increase in hematocrit hemoglobin, and red blood cell volume and a decrease in osmotic resistance while the hemodynamic variables were unchanged. The conclude that, in spite of changes in rheologic variables, increasing viscosity of the blood and thus possibly increasing the peripheral resistance, these had no effect on the cardiovascular state. Erythropoietin treatment improves the subjective well-being in patients on chronic hemodialysis without compromising their cardiovascular function.
OriginalsprogEngelsk
TidsskriftAngiology
Vol/bind45
Udgave nummer3
Sider (fra-til)231-4
Antal sider4
ISSN0003-3197
StatusUdgivet - 1 mar. 1994

ID: 32354124